PR94927

GAITHERSBURG, Md., Mar. 11, 2022 /PRNewswire=KYODO JBN/--

-  'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide

   information regarding vaccines

-  Programs explain Novavax' commitment to vaccine development and innovation

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing

and commercializing next-generation vaccines for serious infectious diseases,

today announced the launch of its global unbranded 'We Do Vaccines' (

https://c212.net/c/link/?t=0&l=en&o=3468579-1&h=397639888&u=http%3A%2F%2Fwww.wedovaccines.com%2F&a=We+Do+Vaccines

) and 'Know Our Vax' (

https://c212.net/c/link/?t=0&l=en&o=3468579-1&h=265655208&u=https%3A%2F%2Fwww.knowourvax.com%2F&a=Know+Our+Vax

) programs, educational efforts aimed to help protect the health of people

everywhere in the fight against COVID-19 and other deadly infectious diseases,

such as influenza.

Photo -

https://mma.prnewswire.com/media/1763609/Novavax_We_Do_Vaccines_Know_Our_Vax_programs.jpg

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

The 'We Do Vaccines' program helps provide educational information about the

common types of vaccines and how they work, how vaccines are made and tested,

and how Novavax' approach to technology makes its vaccines different. The 'Know

Our Vax' program provides educational information about Novavax, its global

approach, and tried and true technology.

"Novavax' vaccines are built on a well-understood protein-based platform used

for other vaccines for decades, and we are committed to fighting the current

pandemic and aiding in overall global public health," said John Trizzino, Chief

Commercial Officer and Chief Business Officer, Novavax. "We're proud to do our

part to ensure that all stakeholders have awareness about their vaccine options

through the launch of educational programs such as these."

The programs intend to inspire people to learn more about how vaccines have

helped millions of lives and encourage those who have not yet been vaccinated

to consider a differentiated option. For additional information, the consumer

website is available at www.wedovaccines.com and the healthcare provider

website is available at www.knowourvax.com.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved

health globally through the discovery, development and commercialization of

innovative vaccines to prevent serious infectious diseases. The company's

proprietary recombinant technology platform harnesses the power and speed of

genetic engineering to efficiently produce highly immunogenic nanoparticles

designed to address urgent global health needs. NVX-CoV2373, the company's

COVID-19 vaccine, has received conditional authorization from multiple

regulatory authorities globally, including the European Commission and the

World Health Organization. The vaccine is also under review by multiple

regulatory agencies worldwide. In addition to its COVID-19 vaccine, Novavax is

also currently evaluating a COVID-seasonal influenza combination vaccine in a

Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu, its

quadrivalent influenza investigational vaccine candidate. These vaccine

candidates incorporate Novavax' proprietary saponin-based Matrix-M(TM) adjuvant

to enhance the immune response and stimulate high levels of neutralizing

antibodies.

For more information, visit: www.novavax.com and connect with us on Twitter (

https://twitter.com/Novavax ) , LinkedIn (

https://www.linkedin.com/company/novavax/ ), Instagram (

https://www.instagram.com/novavax/ ) and Facebook (

https://www.facebook.com/Novavax/ ).

Forward-Looking Statements

Statements herein relating to the future of Novavax, its operating plans and

prospects, its partnerships, the timing of clinical trial results, the ongoing

development of NVX-CoV2373, including a COVID-seasonal influenza combination

vaccine candidate with NanoFlu, its quadrivalent influenza investigational

vaccine candidate, the scope, timing and outcome of future regulatory filings

and actions, the potential impact of Novavax and NVX-CoV2373 in addressing

global vaccine access and education, controlling the pandemic, and protecting

populations, and the efficacy, safety, and intended utilization of NVX-CoV2373

are forward-looking statements. Novavax cautions that these forward-looking

statements are subject to numerous risks and uncertainties that could cause

actual results to differ materially from those expressed or implied by such

statements. These risks and uncertainties include, without limitation,

challenges satisfying, alone or together with partners, various safety,

efficacy, and product characterization requirements, including those related to

process qualification and assay validation, necessary to satisfy applicable

regulatory authorities; unanticipated challenges or delays in conducting

clinical trials; difficulty obtaining scarce raw materials and supplies;

resource constraints, including human capital and manufacturing capacity, on

the ability of Novavax to pursue planned regulatory pathways; challenges

meeting contractual requirements under agreements with multiple commercial,

governmental, and other entities; and those other risk factors identified in

the "Risk Factors" and "Management's Discussion and Analysis of Financial

Condition and Results of Operations" sections of Novavax' Annual Report on Form

10-K for the year ended December 31, 2021, as filed with the Securities and

Exchange Commission (SEC). We caution investors not to place considerable

reliance on forward-looking statements contained in this press release. You are

encouraged to read our filings with the SEC, available at www.sec.gov and

www.novavax.com, for a discussion of these and other risks and uncertainties.

The forward-looking statements in this press release speak only as of the date

of this document, and we undertake no obligation to update or revise any of the

statements. Our business is subject to substantial risks and uncertainties,

including those referenced above. Investors, potential investors, and others

should give careful consideration to these risks and uncertainties.

Contacts:

Investors:

Novavax, Inc.

Erika Schultz

+1-240-268-2022

ir@novavax.com

Solebury Trout

Alexandra Roy

+1-617-221-9197

aroy@soleburytrout.com;

Media:

Ali Chartan

+1-240-720-7804

Laura Keenan Lindsey

+1-202-709-7521

media@novavax.com

SOURCE: Novavax, Inc.